Article Correctness Is Author's Responsibility: ACTG announces the addition of two monoclonal antibodies to ACTIV-2 outpatient treatment study for COVID-19

(AIDS Clinical Trials Group) The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, today announced the addition of two monoclonal antibodies, BMS-986414 and BMS-986413, to the COVID-19 outpatient treatment study, ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial. BMS-986414 and BMS-986413 will be administered as subcutaneous injections (shots) given at one visit. ACTIV-2 includes both phase 2 and phase 3 evaluations of multiple investigational agents for treating early COVID-19 in a single trial.